Oramed Pharmaceuticals reported a significant increase in net income to $134.9 million for the nine months ended September 30, 2026, primarily driven by $180.5 million in financial income. The company's total assets grew to $400.9 million, largely due to substantial increases in the fair value of investments and associates.
Oramed Pharmaceuticals CFO Avraham Gabay Sells $90.2K of Stock
Avraham Gabay, CFO, sold 20,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $90.2K in total on Oct 1, 2026. Shares held after the trade: 861,076 (-2.3%).
Joshua Hexter, COO & Cbo, sold 30,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $135K in total on Oct 1, 2026. Shares held after the trade: 1,328,130 (-2.2%).
Oramed Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 15, 2026, where shareholders re-elected six directors and ratified Kesselman & Kesselman as the independent auditor. Stockholders also approved an amendment to the 2019 Stock Incentive Plan to increase the authorized share pool by 3,000,000 shares and voted to hold future say-on-pay votes every three years.